Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome

Journal of the American Society of Hypertension

Volumn 5, Issue 6, 2011, Pages 489-497

  Weinberger, Myron H ^a   Izzo Jr , Joseph L ^b   Purkayastha, Das ^c   Weitzman, Richard ^c   Black, Henry R ^d  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adverse events; blood pressure; calcium channel blocker; Direct renin inhibitor

Indexed keywords

ALISKIREN PLUS AMLODIPINE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; RENIN INHIBITOR;

ADULT; AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; COMORBIDITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ETHNIC GROUP; FATIGUE; FEMALE; HEADACHE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OBESITY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TABLET; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AMIDES; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; COMORBIDITY; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FUMARATES; HUMANS; HYPERTENSION; LEAST-SQUARES ANALYSIS; METABOLIC SYNDROME X; OBESITY; PROSPECTIVE STUDIES;

EID: 81255188035     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2011.08.005     Document Type: Article

References (19)

1. B.M. Egan, Y. Zhao, and R.N. Axon US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008 JAMA 303 2010 2043 2050
2. K.C. Ferdinand, and A.M. Armani The management of hypertension in African Americans Crit Pathw Cardiol 6 2007 67 71
3. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, R.J. Adams, J.D. Berry, and T.M. Brown Heart disease and stroke statistics - 2011 update: a report from the American Heart Association Circulation 123 2011 e18 e209
4. R.E. Schmieder, and L.M. Ruilope Blood pressure control in patients with comorbidities J Clin Hypertens (Greenwich) 10 2008 624 631
5. J.M. Flack, D.A. Sica, G. Bakris, A.L. Brown, K.C. Ferdinand, and R.H. Grimm Jr. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement Hypertension 56 2010 780 800
6. Z.H. Israili, M. Velasco, and V. Bermúdez Direct renin inhibitors as antihypertensive agents Am J Ther 17 2010 237 254
7. S.T. Duggan, C.M. Chwieduk, and M.P. Curran Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension Drugs 70 2010 2011 2049
8. W.B. White, R. Bresalier, A.P. Kaplan, B.F. Palmer, R.H. Riddell, and A. Lesogor Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension J Clin Hypertens (Greenwich) 12 2010 765 775
9. H.R. Black, M.H. Weinberger, D. Purkayastha, J. Lee, M. Isreal, and R. Hilkert Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension J Clin Hypertens (Greenwich) 13 2011 571 581
10. T.G. Pickering, J.E. Hall, L.J. Appel, B.E. Falkner, J. Graves, and M.N. Hill Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research Circulation 111 2005 697 716
11. W. Drummond, M.A. Munger, E.M. Rafique, M. Maboudian, M. Khan, and D.L. Keefe Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy J Clin Hypertens (Greenwich) 9 2007 742 750
12. T.W. Littlejohn III, P. Trenkwalder, G. Hollanders, Y. Zhao, and W. Liao Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension Curr Med Res Opin 25 2009 951 959
13. R.E. Schmieder, T. Philipp, J. Guerediaga, M. Gorostidi, B. Smith, and N. Weissbach Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide Circulation 119 2009 417 425
14. R.E. Schmieder, T. Philipp, J. Guerediaga, M. Gorostidi, C. Bush, and D.L. Keefe Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial J Hypertens 27 2009 1493 1501
15. Braun-Dullaeus RC, Zhang J, Hristoskova S, Häring DA, Liao W. First-line therapy with aliskiren/amlodipine combination provides robust blood pressure reductions in patients with moderate to severe hypertension. Presented at: 25th Annual Scientific Meeting and Exposition of the American Society of Hypertension. May 1-4, 2010, New York, NY.
16. M.J. Brown, G.T. McInnes, C.C. Papst, J. Zhang, and T.M. MacDonald Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial Lancet 377 2011 312 320
17. K.C. Ferdinand, R. Weitzman, M. Israel, J. Lee, D. Purkayastha, and E.A. Jaimes Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension J Am Soc Hypertens 5 2011 102 113
18. J.W. Ely, J.A. Osheroff, M.L. Chambliss, and M.H. Ebell Approach to leg edema of unclear etiology J Am Board Fam Med 19 2006 148 160
19. L.J. Appel, J.T. Wright Jr., T. Greene, L.Y. Agodoa, B.C. Astor, and G.L. Bakris Intensive blood-pressure control in hypertensive chronic kidney disease N Engl J Med 363 2010 918 929